Several studies have reported disappointing clinical outcomes with lower response rates and shorter survival in patients with EGFR-mutated NSCLC treated with PD-1 inhibitors than in patients with EGFR-wild NSCLC (Bylicki et al. 2017; Gainor et al. 2016; Lee et al. 2018; Santambrogio and Rammensee 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.